Detailed narrative
Atera Launch Momentum and Market Impact
The Atera platform has garnered an "extraordinary customer response" with a "strikingly large number of orders" in a short timeframe, already exceeding the full-year shipment target of 40 units. Atera enables spatial whole transcriptome profiling with single-cell sensitivity at scale, poised to transform biological research by providing a more complete view of biological systems. Customer enthusiasm is evident across universities, academic medical centers, and biopharma companies, spanning nearly every major disease area and research question, from foundational atlassing to biomarker discovery.
Catalyst Research Services and Platform Roadmap
Strong demand is also observed for Catalyst Research Services, which allows customers to submit samples to be run on Atera, serving as a key leading indicator for the platform's future. The company envisions Atera as a long-duration, upgradeable platform with an extensive roadmap including workflow automation, base-by-base spatial sequencing, and protein multiomics, reinforcing its potential for sustained impact.
Strategic Acquisition and Multiomics Expansion
To enhance its proteomics capabilities, 10x Genomics acquired Proteintech Genomics, bringing deep expertise and differentiated technologies for measuring proteins in a multiomic context. This acquisition complements existing multiomics offerings, such as the recently launched GEM-X version of the Multiome product, which significantly improves the ability to measure epigenetics and gene expression from the same cell, unlocking new dimensions of biological context.
AI as a Structural Tailwind for Data Generation
AI represents a significant structural tailwind, driving demand for high-quality biological data. The company's single cell and spatial technologies are foundational for training AI models, as they address the bottleneck of measuring biological systems at massive scale and high resolution. AI's influence is pervasive across the customer base, with most significant biological data generation efforts now conceived with the goal of training AI models, supported by academic, philanthropic, and government funding priorities, as well as rapid growth in biopharma AI investments.
Chromium and Flex Apex Performance
The Single Cell business continues to show sustained strength, particularly in Chromium consumable reaction volumes, driven by the accelerating momentum of Flex Apex. Flex Apex is becoming the standard assay for larger, more ambitious studies and perturbation experiments, especially in biopharma for target identification. This shift, combined with the ability for distributed sample collection and centralized processing, is leading to more centralization towards service providers and core labs, impacting instrument placement dynamics.
Clinical Diagnostics Progress and Partnerships
10x Genomics is making progress in extending its technologies into clinical diagnostics, focusing on generating robust clinical evidence in oncology and autoimmunity. New partnerships with the Cleveland Clinic and Lausanne University Hospital aim to identify biomarkers of response to therapy across multiple oncology indications, demonstrating the company's commitment to future opportunities in this area.